SK1362000A3 - Aryloxyarylsulfonylamino hydroxamic acid derivatives - Google Patents

Aryloxyarylsulfonylamino hydroxamic acid derivatives Download PDF

Info

Publication number: SK1362000A3
Authority: SK; Slovakia
Prior art keywords: compound; amino; fluorophenoxy; compound according; benzenesulfonyl
Prior art date: 1997-08-08

Application number

SK136-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Ralph Pelton Robinson

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-08

Filing date

1998-07-21

Publication date

2000-10-09

1998-07-21 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2000-10-09 Publication of SK1362000A3 publication Critical patent/SK1362000A3/sk

Links

239000002253 acid Substances 0.000 title description 21
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 73
150000003839 salts Chemical class 0.000 claims abstract description 35
-1 trifluoromethoxy, difluoromethoxy Chemical group 0.000 claims abstract description 32
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 25
239000001257 hydrogen Substances 0.000 claims abstract description 25
150000002431 hydrogen Chemical class 0.000 claims abstract description 14
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 11
229910052799 carbon Inorganic materials 0.000 claims abstract description 10
125000001424 substituent group Chemical group 0.000 claims abstract description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 8
125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 5
125000001153 fluoro group Chemical group F* 0.000 claims abstract description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 4
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 3
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims abstract description 3
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims abstract description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 12
QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 11
241000124008 Mammalia Species 0.000 claims description 11
108010076503 Matrix Metalloproteinase 13 Proteins 0.000 claims description 10
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 10
238000000034 method Methods 0.000 claims description 8
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
206010028980 Neoplasm Diseases 0.000 claims description 6
206010003246 arthritis Diseases 0.000 claims description 6
230000005764 inhibitory process Effects 0.000 claims description 6
235000019260 propionic acid Nutrition 0.000 claims description 6
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
230000000694 effects Effects 0.000 claims description 5
VHHGUBHZBLPTKL-UHFFFAOYSA-N Cp-471358 Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCCC1 VHHGUBHZBLPTKL-UHFFFAOYSA-N 0.000 claims description 4
LLMCVPDKPNDQCK-UHFFFAOYSA-N ethyl 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(hydroxycarbamoyl)cyclopentyl]amino]propanoate Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(=O)OCC)C1(C(=O)NO)CCCC1 LLMCVPDKPNDQCK-UHFFFAOYSA-N 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
NMDUJEUWNLCXSB-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(hydroxyamino)-2-methyl-1-oxopropan-2-yl]amino]propanoic acid Chemical compound C1=CC(S(=O)(=O)N(CCC(O)=O)C(C)(C)C(=O)NO)=CC=C1OC1=CC=C(F)C=C1 NMDUJEUWNLCXSB-UHFFFAOYSA-N 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
102000011722 Matrix Metalloproteinase 13 Human genes 0.000 claims 4
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
239000000243 solution Substances 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
238000006243 chemical reaction Methods 0.000 description 15
102100027995 Collagenase 3 Human genes 0.000 description 14
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
239000003112 inhibitor Substances 0.000 description 13
239000000203 mixture Substances 0.000 description 13
102000029816 Collagenase Human genes 0.000 description 12
108060005980 Collagenase Proteins 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
229960002424 collagenase Drugs 0.000 description 12
239000002585 base Substances 0.000 description 11
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
239000002904 solvent Substances 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 7
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 7
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
150000007513 acids Chemical class 0.000 description 7
239000012267 brine Substances 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
229910052943 magnesium sulfate Inorganic materials 0.000 description 7
235000019341 magnesium sulphate Nutrition 0.000 description 7
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000000758 substrate Substances 0.000 description 7
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 6
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
150000001447 alkali salts Chemical class 0.000 description 6
238000003556 assay Methods 0.000 description 6
238000001704 evaporation Methods 0.000 description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
231100000252 nontoxic Toxicity 0.000 description 6
230000003000 nontoxic effect Effects 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000000651 prodrug Substances 0.000 description 6
229940002612 prodrug Drugs 0.000 description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
208000025865 Ulcer Diseases 0.000 description 5
239000002798 polar solvent Substances 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
102000003390 tumor necrosis factor Human genes 0.000 description 5
230000036269 ulceration Effects 0.000 description 5
108050005238 Collagenase 3 Proteins 0.000 description 4
101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
229910052784 alkaline earth metal Inorganic materials 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
150000007514 bases Chemical class 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
150000001768 cations Chemical class 0.000 description 4
125000004494 ethyl ester group Chemical group 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
208000028169 periodontal disease Diseases 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
239000000047 product Substances 0.000 description 4
239000000376 reactant Substances 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
206010053177 Epidermolysis Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
230000033115 angiogenesis Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000012131 assay buffer Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000007943 implant Substances 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000011591 potassium Substances 0.000 description 3
208000037803 restenosis Diseases 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000006386 Bone Resorption Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
239000003810 Jones reagent Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
101150014058 MMP1 gene Proteins 0.000 description 2
102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
229910002651 NO3 Inorganic materials 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000003513 alkali Substances 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
CUQBVKOADUOKPT-UHFFFAOYSA-N benzyl 1-[(3-ethoxy-3-oxopropyl)-[4-(4-fluorophenoxy)phenyl]sulfonylamino]cyclopentane-1-carboxylate Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(=O)OCC)C1(C(=O)OCC=2C=CC=CC=2)CCCC1 CUQBVKOADUOKPT-UHFFFAOYSA-N 0.000 description 2
HTOKUOTYXJUXSH-UHFFFAOYSA-N benzyl 1-[[4-(4-fluorophenoxy)phenyl]sulfonyl-(3-hydroxypropyl)amino]cyclopentane-1-carboxylate Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCCO)C1(C(=O)OCC=2C=CC=CC=2)CCCC1 HTOKUOTYXJUXSH-UHFFFAOYSA-N 0.000 description 2
ICKPCMLGESBARJ-UHFFFAOYSA-N benzyl 1-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]cyclopentane-1-carboxylate Chemical compound C1=CC(F)=CC=C1OC1=CC=C(S(=O)(=O)NC2(CCCC2)C(=O)OCC=2C=CC=CC=2)C=C1 ICKPCMLGESBARJ-UHFFFAOYSA-N 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
230000024279 bone resorption Effects 0.000 description 2
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
229910000024 caesium carbonate Inorganic materials 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
108700004333 collagenase 1 Proteins 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentane carboxylic acid Natural products OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
229910052805 deuterium Inorganic materials 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
ZUHKQEYBHFAYKI-UHFFFAOYSA-N ethyl 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(hydroxyamino)-2-methyl-1-oxopropan-2-yl]amino]propanoate Chemical compound C1=CC(S(=O)(=O)N(C(C)(C)C(=O)NO)CCC(=O)OCC)=CC=C1OC1=CC=C(F)C=C1 ZUHKQEYBHFAYKI-UHFFFAOYSA-N 0.000 description 2
MNJQUXGHECPALD-UHFFFAOYSA-N ethyl 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(phenylmethoxycarbamoyl)cyclopentyl]amino]propanoate Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(=O)OCC)C1(C(=O)NOCC=2C=CC=CC=2)CCCC1 MNJQUXGHECPALD-UHFFFAOYSA-N 0.000 description 2
230000005284 excitation Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
238000007327 hydrogenolysis reaction Methods 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000011707 mineral Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000013641 positive control Substances 0.000 description 2
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
PMKSWPOIJXENOZ-UHFFFAOYSA-N 1-(4-aminophenoxy)ethane-1,1-diol Chemical compound CC(O)(O)OC1=CC=C(N)C=C1 PMKSWPOIJXENOZ-UHFFFAOYSA-N 0.000 description 1
HGMRCAGQEDXAGL-UHFFFAOYSA-N 1-[(3-ethoxy-3-oxopropyl)-[4-(4-fluorophenoxy)phenyl]sulfonylamino]cyclopentane-1-carboxylic acid Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(=O)OCC)C1(C(O)=O)CCCC1 HGMRCAGQEDXAGL-UHFFFAOYSA-N 0.000 description 1
LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical class C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-L 2-(carboxymethyl)-2-hydroxysuccinate Chemical compound [O-]C(=O)CC(O)(C(=O)O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-L 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical class C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
IPLZEJYVLISRGV-UHFFFAOYSA-N 3-[[1-(hydroxycarbamoyl)cyclopentyl]-(4-phenoxyphenyl)sulfonylamino]propanoic acid Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCCC1 IPLZEJYVLISRGV-UHFFFAOYSA-N 0.000 description 1
JWRMPLBCMHSOLA-UHFFFAOYSA-N 3-[[4-(4-chlorophenoxy)phenyl]sulfonyl-[1-(hydroxyamino)-2-methyl-1-oxopropan-2-yl]amino]propanoic acid Chemical compound C1=CC(S(=O)(=O)N(CCC(O)=O)C(C)(C)C(=O)NO)=CC=C1OC1=CC=C(Cl)C=C1 JWRMPLBCMHSOLA-UHFFFAOYSA-N 0.000 description 1
OCMKRLWZPHPYPX-UHFFFAOYSA-N 3-[[4-(4-chlorophenoxy)phenyl]sulfonyl-[1-(hydroxycarbamoyl)cyclopentyl]amino]propanoic acid Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCCC1 OCMKRLWZPHPYPX-UHFFFAOYSA-N 0.000 description 1
RLAPMRSVBPMTKC-UHFFFAOYSA-N 3-[[4-(4-chlorophenoxy)phenyl]sulfonyl-[4-(hydroxycarbamoyl)oxan-4-yl]amino]propanoic acid Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCOCC1 RLAPMRSVBPMTKC-UHFFFAOYSA-N 0.000 description 1
UEPYWXABDJPBDY-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-(1-phenylmethoxycarbonylcyclopentyl)amino]propanoic acid Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(=O)O)C1(C(=O)OCC=2C=CC=CC=2)CCCC1 UEPYWXABDJPBDY-UHFFFAOYSA-N 0.000 description 1
AXBZHDYBORSFHG-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(hydroxycarbamoyl)cyclohexyl]amino]propanoic acid Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCCCC1 AXBZHDYBORSFHG-UHFFFAOYSA-N 0.000 description 1
WARXYAHFCARUNH-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[4-(hydroxycarbamoyl)oxan-4-yl]amino]propanoic acid Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCOCC1 WARXYAHFCARUNH-UHFFFAOYSA-N 0.000 description 1
CECDVQVSYQTBIH-UHFFFAOYSA-N 3-[[4-(hydroxycarbamoyl)oxan-4-yl]-(4-phenoxyphenyl)sulfonylamino]propanoic acid Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCOCC1 CECDVQVSYQTBIH-UHFFFAOYSA-N 0.000 description 1
FSQZFEUUKBMFFB-UHFFFAOYSA-N 3-iodopropoxy(dimethyl)silane Chemical compound C[SiH](C)OCCCI FSQZFEUUKBMFFB-UHFFFAOYSA-N 0.000 description 1
UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 1
PDAYRCHIAPCRRD-UHFFFAOYSA-N 4-(4-fluorophenoxy)benzenesulfonyl chloride Chemical compound C1=CC(F)=CC=C1OC1=CC=C(S(Cl)(=O)=O)C=C1 PDAYRCHIAPCRRD-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000002583 angiography Methods 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
RGCVAQJHOXBYFL-UHFFFAOYSA-N benzyl 1-[3-[tert-butyl(dimethyl)silyl]oxypropyl-[4-(4-fluorophenoxy)phenyl]sulfonylamino]cyclopentane-1-carboxylate Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCCO[Si](C)(C)C(C)(C)C)C1(C(=O)OCC=2C=CC=CC=2)CCCC1 RGCVAQJHOXBYFL-UHFFFAOYSA-N 0.000 description 1
LXWREXKYHMWQRO-UHFFFAOYSA-N benzyl 1-aminocyclopentane-1-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)C1(N)CCCC1 LXWREXKYHMWQRO-UHFFFAOYSA-N 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 description 1
239000012496 blank sample Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940117975 chromium trioxide Drugs 0.000 description 1
WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical class CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
VSJYBCNCYFOGJA-UHFFFAOYSA-N ethyl 3-[[4-(hydroxycarbamoyl)oxan-4-yl]-(4-phenoxyphenyl)sulfonylamino]propanoate Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1S(=O)(=O)N(CCC(=O)OCC)C1(C(=O)NO)CCOCC1 VSJYBCNCYFOGJA-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
150000004694 iodide salts Chemical class 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
LVCDXCQFSONNDO-UHFFFAOYSA-N n-benzylhydroxylamine Chemical compound ONCC1=CC=CC=C1 LVCDXCQFSONNDO-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001184 polypeptide Chemical group 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000765 processed proteins & peptides Chemical group 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
108091007196 stromelysin Proteins 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
KTJOZDBANQOLHP-UHFFFAOYSA-N tert-butyl-(3-iodopropoxy)-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCI KTJOZDBANQOLHP-UHFFFAOYSA-N 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
DRDCQJADRSJFFD-UHFFFAOYSA-N tris-hydroxymethyl-methyl-ammonium Chemical class OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Surgery (AREA)
Immunology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Pyrane Compounds (AREA)

SK136-2000A 1997-08-08 1998-07-21 Aryloxyarylsulfonylamino hydroxamic acid derivatives SK1362000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5520797P	1997-08-08	1997-08-08
PCT/IB1998/001113 WO1999007675A1 (fr)	1997-08-08	1998-07-21	Derives de l'acide aryloxyarylsulfonylamino hydroxamique

Publications (1)

Publication Number	Publication Date
SK1362000A3 true SK1362000A3 (en)	2000-10-09

Family

ID=21996358

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK136-2000A SK1362000A3 (en)	1997-08-08	1998-07-21	Aryloxyarylsulfonylamino hydroxamic acid derivatives

Country Status (42)

Country	Link
US (1)	US6214872B1 (fr)
EP (1)	EP1003720B1 (fr)
JP (1)	JP3448275B2 (fr)
KR (1)	KR100372138B1 (fr)
CN (1)	CN1171866C (fr)
AP (1)	AP1220A (fr)
AR (1)	AR015419A1 (fr)
AT (1)	ATE263147T1 (fr)
AU (1)	AU730248B2 (fr)
BG (1)	BG104118A (fr)
BR (1)	BR9811868A (fr)
CA (1)	CA2299355C (fr)
CO (1)	CO4960658A1 (fr)
DE (1)	DE69822839T2 (fr)
DK (1)	DK1003720T3 (fr)
DZ (1)	DZ2581A1 (fr)
EA (1)	EA002490B1 (fr)
ES (1)	ES2216293T3 (fr)
GT (1)	GT199800124A (fr)
HR (1)	HRP980438B1 (fr)
HU (1)	HUP0002960A3 (fr)
ID (1)	ID23668A (fr)
IL (1)	IL134300A (fr)
IS (1)	IS5340A (fr)
MA (1)	MA26530A1 (fr)
MY (1)	MY120235A (fr)
NO (1)	NO313189B1 (fr)
NZ (1)	NZ502309A (fr)
OA (1)	OA11284A (fr)
PA (1)	PA8456801A1 (fr)
PE (1)	PE110899A1 (fr)
PL (1)	PL338633A1 (fr)
PT (1)	PT1003720E (fr)
SK (1)	SK1362000A3 (fr)
TN (1)	TNSN98150A1 (fr)
TR (1)	TR200000368T2 (fr)
TW (1)	TW426662B (fr)
UA (1)	UA61963C2 (fr)
UY (2)	UY25131A1 (fr)
WO (1)	WO1999007675A1 (fr)
YU (1)	YU1900A (fr)
ZA (1)	ZA987126B (fr)

Families Citing this family (205)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT199900044A (es) *	1998-04-10	2000-09-14		Procedimientos para preparar haluros de fenoxifenilsulfonilo.
PA8469601A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Procedimiento para alquilar sulfonamidas impedidas estericamente
DK0952148T3 (da) *	1998-04-10	2004-09-20	Pfizer Prod Inc	Cyclobutylaryloxyarylsulfonylaminohydroxamsyrederivater
PA8469301A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Procedimientos para la preparacion de acidos hidroxamicos.
WO2000058280A1 (fr) *	1999-03-26	2000-10-05	Shionogi & Co., Ltd.	Derives de sulfonamide carbocyclique
WO2000058278A1 (fr) *	1999-03-26	2000-10-05	Shionogi & Co., Ltd.	Derives d'acides amines $g(b)
PT1041072E (pt) *	1999-03-31	2003-11-28	Pfizer Prod Inc	Acidos dioxociclopentil hidroxamicos
WO2001012592A2 (fr)	1999-08-18	2001-02-22	Warner-Lambert Company	Composes d'acide hydroxamique utiles comme inhibiteurs de metalloproteinases matricielles
IL138686A0 (en) *	1999-10-01	2001-10-31	Pfizer Prod Inc	α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
ES2344592T3 (es)	2001-01-05	2010-09-01	Pfizer Inc.	Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
DE60236350D1 (de) *	2001-03-14	2010-06-24	Novartis Ag	Azacycloalkyl-substituierte essigsäure-derivate zur verwendung als mmp-inhibitoren
AU2002345792A1 (en)	2001-06-21	2003-01-08	Pfizer Inc.	Thienopyridine and thienopyrimidine anticancer agents
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
CA2471814C (fr)	2001-12-27	2011-03-15	Sumitomo Pharmaceuticals Co., Ltd.	Derives d'acide hydroxamique et inhibiteur des mmp contenant ces derniers en tant que substance active
BR0317548A (pt)	2002-12-19	2005-11-22	Pfizer	Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
GB0326546D0 (en) *	2003-11-14	2003-12-17	Amersham Plc	Inhibitor imaging agents
KR101099849B1 (ko)	2003-11-19	2011-12-28	어레이 바이오파마 인크.	Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US20080095704A1 (en) *	2004-07-02	2008-04-24	Alan Cuthbertson	Imaging Agents with Improved Pharmacokinetic Profiles
RU2342159C2 (ru)	2004-07-16	2008-12-27	Пфайзер Продактс Инк.	Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
CN101023064B (zh)	2004-08-26	2011-02-16	辉瑞大药厂	作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
US7429667B2 (en)	2005-01-20	2008-09-30	Ardea Biosciences, Inc.	Phenylamino isothiazole carboxamidines as MEK inhibitors
UA100007C2 (ru)	2005-05-18	2012-11-12	Астразенека Аб	Гетероциклические ингибиторы мек, их применение и фармацевтическая композиция, которая их содержит
US8101799B2 (en)	2005-07-21	2012-01-24	Ardea Biosciences	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2007035744A1 (fr)	2005-09-20	2007-03-29	Osi Pharmaceuticals, Inc.	Marqueurs biologiques predictifs d'une reaction anticancereuse aux inhibiteurs kinase du recepteur du facteur de croissance 1 analogue a l'insuline
WO2007121269A2 (fr)	2006-04-11	2007-10-25	Ardea Biosciences, Inc.	N-aryl-n'alkyle sulfamides utilisés comme inhibiteurs de mek
JP5269762B2 (ja)	2006-04-18	2013-08-21	アーディア・バイオサイエンシーズ・インコーポレイテッド	Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
ES2547303T3 (es)	2007-01-19	2015-10-05	Ardea Biosciences, Inc.	Inhibidores de MEK
UA97834C2 (ru)	2007-04-18	2012-03-26	Пфайзер Продактс Инк.	Производные сульфониламида для лечения анормального роста клеток
US8530463B2 (en)	2007-05-07	2013-09-10	Hale Biopharma Ventures Llc	Multimodal particulate formulations
CA2706571C (fr)	2007-12-19	2012-11-27	Genentech, Inc.	5-anilinoimidazopyridines et procedes d'utilisation
EP2220092B1 (fr)	2007-12-21	2012-06-06	Genentech, Inc.	Azaindolizines et procédés d'utilisation
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2586032T3 (es)	2008-03-28	2016-10-11	Hale Biopharma Ventures, Llc	Administración de composiciones de benzodiazepinas
ES2604668T3 (es)	2009-02-05	2017-03-08	Immunogen, Inc.	Nuevos derivados de benzodiacepina
JP2012518657A (ja)	2009-02-25	2012-08-16	オーエスアイ・ファーマシューティカルズ，エルエルシー	併用抗癌治療
WO2010099137A2 (fr)	2009-02-26	2010-09-02	Osi Pharmaceuticals, Inc.	Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo
WO2010099138A2 (fr)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
JP2012519281A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099364A2 (fr)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
US20120128670A1 (en)	2009-07-31	2012-05-24	OSI Pharmaceuticals, LLC	mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
ES2534358T3 (es)	2009-10-13	2015-04-21	Allomek Therapeutics, Llc	Inhibidores novedosos de MEK útiles en el tratamiento de enfermedades
KR102012398B1 (ko)	2009-11-05	2019-08-20	리젠 파마슈티컬스 소시에떼 아노님	신규한 벤조피란 키나제 조절제
TW201141536A (en)	2009-12-21	2011-12-01	Colgate Palmolive Co	Oral care compositions and methods
WO2011100403A1 (fr)	2010-02-10	2011-08-18	Immunogen, Inc	Anticorps anti-cd20 et utilisations de ceux-ci
MX343383B (es)	2010-02-12	2016-11-03	Pfizer Inc *	Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona.
CA2783665A1 (fr)	2010-03-03	2011-09-09	OSI Pharmaceuticals, LLC	Marqueurs biologiques predictifs d'une reponse anticancereuse aux inhibiteurs de kinase du recepteur du facteur de croissance insulinique 1
US20110275644A1 (en)	2010-03-03	2011-11-10	Buck Elizabeth A	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
ES2695899T3 (es)	2010-06-16	2019-01-11	Univ Pittsburgh Commonwealth Sys Higher Education	Anticuerpos contra endoplasmina y su uso
NZ612909A (en)	2011-01-10	2015-09-25	Infinity Pharmaceuticals Inc	Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN113896731A (zh)	2011-02-15	2022-01-07	伊缪诺金公司	细胞毒性苯并二氮杂䓬衍生物
WO2012116040A1 (fr)	2011-02-22	2012-08-30	OSI Pharmaceuticals, LLC	Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire
US9127000B2 (en)	2011-02-23	2015-09-08	Intellikine, LLC.	Heterocyclic compounds and uses thereof
EP2702173A1 (fr)	2011-04-25	2014-03-05	OSI Pharmaceuticals, LLC	Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
CN107737100A (zh)	2011-06-14	2018-02-27	哈尔生物药投资有限责任公司	苯二氮卓组合物的投与
US9416132B2 (en)	2011-07-21	2016-08-16	Tolero Pharmaceuticals, Inc.	Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
US9630979B2 (en)	2011-09-29	2017-04-25	Infinity Pharmaceuticals, Inc.	Inhibitors of monoacylglycerol lipase and methods of their use
EP2817004B1 (fr)	2012-02-22	2018-04-11	The Regents of The University of Colorado, A Body Corporate	Dérivés de bouvardine et leurs utilisations thérapeutiques
US9452215B2 (en)	2012-02-22	2016-09-27	The Regents Of The University Of Colorado	Bourvadin derivatives and therapeutic uses thereof
WO2013152252A1 (fr)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Polythérapie antinéoplasique
KR102172897B1 (ko)	2012-06-08	2020-11-02	서트로 바이오파마, 인크.	부위-특이적 비-천연 아미노산 잔기를 포함하는 항체, 그의 제조 방법 및 그의 사용 방법
EP3135690A1 (fr)	2012-06-26	2017-03-01	Sutro Biopharma, Inc.	Proteines fc modifiees contenant des residus specifiques d'acides amines non naturels, leurs conjugues, leurs procedes de preparation et leurs procedes d'utilisation
HK1211208A1 (zh)	2012-08-22	2016-05-20	Immunogen, Inc.	細胞毒性苯並二氮呯衍生物
DK3584255T3 (da)	2012-08-31	2022-04-04	Sutro Biopharma Inc	Modificerede aminosyrer omfattende en azidogruppe
ES2644758T3 (es)	2012-10-16	2017-11-30	Tolero Pharmaceuticals, Inc.	Moduladores de PKM2 y métodos para su uso
JP6423804B2 (ja)	2013-02-28	2018-11-14	イミュノジェン・インコーポレーテッド	細胞結合剤及び細胞毒性剤を含む複合体
US9999680B2 (en)	2013-02-28	2018-06-19	Immunogen, Inc.	Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
KR20210149232A (ko)	2013-03-14	2021-12-08	스미토모 다이니폰 파마 온콜로지, 인크.	Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
WO2014143659A1 (fr)	2013-03-15	2014-09-18	Araxes Pharma Llc	Inhibiteurs covalents irréversibles de la gtpase k-ras g12c
US9227978B2 (en)	2013-03-15	2016-01-05	Araxes Pharma Llc	Covalent inhibitors of Kras G12C
WO2014194030A2 (fr)	2013-05-31	2014-12-04	Immunogen, Inc.	Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
EP3019522B1 (fr)	2013-07-10	2017-12-13	Sutro Biopharma, Inc.	Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
JO3805B1 (ar)	2013-10-10	2021-01-31	Araxes Pharma Llc	مثبطات كراس جي12سي
EP3055298B1 (fr)	2013-10-11	2020-04-29	Sutro Biopharma, Inc.	Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
JO3556B1 (ar)	2014-09-18	2020-07-05	Araxes Pharma Llc	علاجات مدمجة لمعالجة السرطان
US10011600B2 (en)	2014-09-25	2018-07-03	Araxes Pharma Llc	Methods and compositions for inhibition of Ras
AR102094A1 (es)	2014-09-25	2017-02-01	Araxes Pharma Llc	Inhibidores de proteínas kras con una mutación g12c
WO2016097918A1 (fr)	2014-12-18	2016-06-23	Pfizer Inc.	Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
US10246424B2 (en)	2015-04-10	2019-04-02	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use thereof
CA2982360A1 (fr)	2015-04-15	2016-10-20	Liansheng Li	Inhibiteurs tricycliques condenses de kras et procedes pour les utiliser
BR112017022666A8 (pt)	2015-04-20	2022-10-18	Tolero Pharmaceuticals Inc	Preparando resposta à alvocidib por perfilamento mitocondrial
CN107849073B (zh)	2015-05-18	2020-04-03	特雷罗药物股份有限公司	具有增加的生物利用度的阿伏西地前药
US10144724B2 (en)	2015-07-22	2018-12-04	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use thereof
CA2993659A1 (fr)	2015-08-03	2017-02-09	Tolero Pharmaceuticals, Inc.	Therapies combinatoires pour le traitement du cancer
WO2017058792A1 (fr)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibiteurs de protéines kras portant la mutation g12c
US10689356B2 (en)	2015-09-28	2020-06-23	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
WO2017058728A1 (fr)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibiteurs de protéines kras portant la mutation g12c
EP3356347A1 (fr)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibiteurs de protéines kras portant la mutation g12c
US10647703B2 (en)	2015-09-28	2020-05-12	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (fr)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibiteurs de protéines kras portant la mutation g12c
US10975071B2 (en)	2015-09-28	2021-04-13	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
WO2017070256A2 (fr)	2015-10-19	2017-04-27	Araxes Pharma Llc	Méthode de criblage d'inhibiteurs de ras
EP3377481A1 (fr)	2015-11-16	2018-09-26	Araxes Pharma LLC	Composés quinazoline substitués en position 2 comprenant un groupe hétérocyclique substitué et leur méthode d'utilisation
MX2018006781A (es)	2015-12-03	2018-11-09	Agios Pharmaceuticals Inc	Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
WO2017100546A1 (fr)	2015-12-09	2017-06-15	Araxes Pharma Llc	Procédés de préparation de dérivés de quinazoléine
CA3011455A1 (fr)	2016-01-27	2017-08-03	Sutro Biopharma, Inc.	Conjugues d'anticorps anti-cd74, compositions comprenant des conjugues d'anticorps anti-cd74 et methodes d'utilisations desdits conjugues d'anticorps anti-cd74
US10822312B2 (en)	2016-03-30	2020-11-03	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use
WO2017197240A1 (fr)	2016-05-12	2017-11-16	The Regents Of The University Of Michigan	Inhibiteurs de ash1l et méthodes de traitement au moyen de ceux-ci
US11118233B2 (en)	2016-05-18	2021-09-14	The University Of Chicago	BTK mutation and ibrutinib resistance
US10646488B2 (en)	2016-07-13	2020-05-12	Araxes Pharma Llc	Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018045379A1 (fr)	2016-09-02	2018-03-08	Dana-Farber Cancer Institute, Inc.	Composition et méthodes de traitement des déreglements des lymphocytes b
CN110036010A (zh)	2016-09-29	2019-07-19	亚瑞克西斯制药公司	Kras g12c突变蛋白的抑制剂
US10377743B2 (en)	2016-10-07	2019-08-13	Araxes Pharma Llc	Inhibitors of RAS and methods of use thereof
WO2018094275A1 (fr)	2016-11-18	2018-05-24	Tolero Pharmaceuticals, Inc.	Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases
CN110234659A (zh)	2016-12-19	2019-09-13	特雷罗药物股份有限公司	用于敏感性分析的分析肽和方法
CN116606261A (zh)	2016-12-22	2023-08-18	美国安进公司	Kras g12c抑制剂及其使用方法
US11279689B2 (en)	2017-01-26	2022-03-22	Araxes Pharma Llc	1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
WO2018140599A1 (fr)	2017-01-26	2018-08-02	Araxes Pharma Llc	Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation
EP3573970A1 (fr)	2017-01-26	2019-12-04	Araxes Pharma LLC	Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer
AU2018213718B2 (en)	2017-01-26	2022-08-25	Zlip Holding Limited	CD47 antigen binding unit and uses thereof
WO2018140512A1 (fr)	2017-01-26	2018-08-02	Araxes Pharma Llc	Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation
JP7327802B2 (ja)	2017-01-26	2023-08-16	アラクセスファーマエルエルシー	縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
EP3601249A4 (fr)	2017-03-24	2020-12-16	Kura Oncology, Inc.	Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
CN110869357A (zh)	2017-05-25	2020-03-06	亚瑞克西斯制药公司	化合物及其用于治疗癌症的使用方法
WO2018218069A1 (fr)	2017-05-25	2018-11-29	Araxes Pharma Llc	Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants
MX2019013954A (es)	2017-05-25	2020-08-31	Araxes Pharma Llc	Inhibidores covalentes de kras.
WO2018226976A1 (fr)	2017-06-08	2018-12-13	Kura Oncology, Inc.	Procédés et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
WO2019023316A1 (fr)	2017-07-26	2019-01-31	Sutro Biopharma, Inc.	Méthodes d'utilisation d'anticorps anti-cd74 et de conjugués d'anticorps dans le traitement d'un lymphome à cellules t
CA3075046A1 (fr)	2017-09-08	2019-03-14	Amgen Inc.	Inhibiteurs de kras g12c et leurs procedes d'utilisation
JP7196160B2 (ja)	2017-09-12	2022-12-26	スミトモファーマオンコロジー，インコーポレイテッド	Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2019055931A1 (fr)	2017-09-18	2019-03-21	Sutro Biopharma, Inc.	Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
US11649251B2 (en)	2017-09-20	2023-05-16	Kura Oncology, Inc.	Substituted inhibitors of menin-MLL and methods of use
US11110177B2 (en)	2017-11-10	2021-09-07	The Regents Of The University Of Michigan	ASH1L degraders and methods of treatment therewith
EP3773591A4 (fr)	2018-04-05	2021-12-22	Sumitomo Dainippon Pharma Oncology, Inc.	Inhibiteurs de kinases axl et leur utilisation
MX2020010836A (es)	2018-05-04	2021-01-08	Amgen Inc	Inhibidores de kras g12c y métodos para su uso.
AU2019262599B2 (en)	2018-05-04	2023-10-12	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
MA52564A (fr)	2018-05-10	2021-03-17	Amgen Inc	Inhibiteurs de kras g12c pour le traitement du cancer
MX2020012731A (es)	2018-06-01	2021-02-22	Amgen Inc	Inhibidores de kras g12c y metodos para su uso.
JP2021527064A (ja)	2018-06-07	2021-10-11	ザリージェンツオブザユニバーシティオブミシガン	Ｐｒｃ１阻害剤及びそれを用いた治療方法
WO2019241157A1 (fr)	2018-06-11	2019-12-19	Amgen Inc.	Inhibiteurs de kras g12c pour le traitement du cancer
JP7369719B2 (ja)	2018-06-12	2023-10-26	アムジエン・インコーポレーテツド	ＫＲａｓＧ１２Ｃ阻害剤及びそれを使用する方法
AU2019310590A1 (en)	2018-07-26	2021-01-14	Sumitomo Pharma Oncology, Inc.	Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
CA3107168A1 (fr)	2018-08-01	2020-02-06	Araxes Pharma Llc	Composes heterocycliques spiro et procedes d'utilisation correspondants pour le traitement du cancer
EP3852811A1 (fr)	2018-09-17	2021-07-28	Sutro Biopharma, Inc.	Polythérapies avec des conjugués d'anticorps anti-récepteur du folate
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020106640A1 (fr)	2018-11-19	2020-05-28	Amgen Inc.	Inhibiteurs de kras g12c et leurs procédés d'utilisation
CA3119807A1 (fr)	2018-12-04	2020-06-11	Sumitomo Dainippon Pharma Oncology, Inc.	Inhibiteurs de cdk9 et leurs polymorphes destines a etre utilises en tant qu'agents pour le traitement du cancer
CN120398830A (zh)	2018-12-20	2025-08-01	美国安进公司	Kif18a抑制剂
WO2020132653A1 (fr)	2018-12-20	2020-06-25	Amgen Inc.	Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
AU2019403488B2 (en)	2018-12-20	2025-07-24	Amgen Inc.	KIF18A inhibitors
MA54546A (fr)	2018-12-20	2022-03-30	Amgen Inc	Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
CN113412262A (zh)	2019-02-12	2021-09-17	大日本住友制药肿瘤公司	包含杂环蛋白激酶抑制剂的制剂
US20230096028A1 (en)	2019-03-01	2023-03-30	Revolution Medicines, Inc.	Bicyclic heterocyclyl compounds and uses thereof
KR20210146287A (ko)	2019-03-01	2021-12-03	레볼루션 메디슨즈, 인크.	이환식 헤테로아릴 화합물 및 이의 용도
WO2020191326A1 (fr)	2019-03-20	2020-09-24	Sumitomo Dainippon Pharma Oncology, Inc.	Traitement de la leucémie myéloïde aiguë (aml) après échec du vénétoclax
CN113747895A (zh)	2019-03-22	2021-12-03	大日本住友制药肿瘤公司	包含pkm2调节剂的组合物和用其治疗的方法
WO2020227105A1 (fr)	2019-05-03	2020-11-12	Sutro Biopharma, Inc.	Conjugués d'anticorps anti-bcma
EP3738593A1 (fr)	2019-05-14	2020-11-18	Amgen, Inc	Dosage d'inhibiteur de kras pour le traitement de cancers
UA129871C2 (uk)	2019-05-21	2025-08-27	Емджен Інк.	Тверді форми
JP2022539208A (ja)	2019-07-03	2022-09-07	スミトモファーマオンコロジー，インコーポレイテッド	チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
CN114401953A (zh)	2019-08-02	2022-04-26	美国安进公司	Kif18a抑制剂
CA3147451A1 (fr)	2019-08-02	2021-02-11	Amgen Inc.	Inhibiteurs de kif18a
EP4007638A1 (fr)	2019-08-02	2022-06-08	Amgen Inc.	Dérivés de pyridine en tant qu'inhibiteurs de kif18a
US20220289724A1 (en)	2019-08-02	2022-09-15	Amgen Inc.	Kif18a inhibitors
EP4031542B1 (fr)	2019-09-18	2025-10-15	Merck Sharp & Dohme LLC	Petites molécules inhibitrices de mutant de kras g12c
CA3155857A1 (fr)	2019-10-24	2021-04-29	Amgen Inc.	Derives de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer
GEP20247710B (en)	2019-10-28	2024-12-25	Merck Sharp & Dohme Llc	Small molecule inhibitors of kras g12c mutant
EP4051266A1 (fr)	2019-10-31	2022-09-07	Taiho Pharmaceutical Co., Ltd.	Dérivés de 4-aminobut-2-enamide et sels de ces derniers
CR20220240A (es)	2019-11-04	2022-08-03	Revolution Medicines Inc	Inhibidores de ras
JP2022553859A (ja)	2019-11-04	2022-12-26	レボリューションメディシンズインコーポレイテッド	Ｒａｓ阻害剤
CA3159561A1 (fr)	2019-11-04	2021-05-14	Revolution Medicines, Inc.	Inhibiteurs de ras
PH12022551102A1 (en)	2019-11-08	2023-11-20	Revolution Medicines Inc	Bicyclic heteroaryl compounds and uses thereof
AU2020383535A1 (en)	2019-11-14	2022-05-05	Amgen Inc.	Improved synthesis of KRAS G12C inhibitor compound
EP4058453A1 (fr)	2019-11-14	2022-09-21	Amgen Inc.	Synthèse améliorée de composé inhibiteur de kras g12c
CN114980976A (zh)	2019-11-27	2022-08-30	锐新医药公司	共价ras抑制剂及其用途
WO2021106231A1 (fr)	2019-11-29	2021-06-03	Taiho Pharmaceutical Co., Ltd.	Composé ayant une activité inhibitrice contre la mutation kras g12d
CN114929279A (zh)	2020-01-07	2022-08-19	锐新医药公司	Shp2抑制剂给药和治疗癌症的方法
WO2021155006A1 (fr)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
EP4114852A1 (fr)	2020-03-03	2023-01-11	Sutro Biopharma, Inc.	Anticorps comprenant des étiquettes de glutamine spécifiques à un site, leurs procédés de préparation et d'utilisation
WO2021215545A1 (fr)	2020-04-24	2021-10-28	Taiho Pharmaceutical Co., Ltd.	Polythérapie anticancéreuse avec un inhibiteur de n-(1-acryloyl-azétidin-3-yl)-2-((1h-indazol-3-yl) amino) méthyl)-1 h-imidazole-5-carboxamide de kras-g12c
WO2021215544A1 (fr)	2020-04-24	2021-10-28	Taiho Pharmaceutical Co., Ltd.	Inhibiteurs de protéine kras g12d
IL299131A (en)	2020-06-18	2023-02-01	Revolution Medicines Inc	Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
CN116113406B (zh)	2020-07-10	2025-08-29	密歇根大学董事会	Gas41抑制剂及其使用方法
US20230255972A1 (en)	2020-07-15	2023-08-17	Taiho Pharmaceutical Co., Ltd.	Pyrimidine compound-containing combination to be used in tumor treatment
CN116209438A (zh)	2020-09-03	2023-06-02	锐新医药公司	使用sos1抑制剂治疗具有shp2突变的恶性疾病
CN116457358A (zh)	2020-09-15	2023-07-18	锐新医药公司	作为ras抑制剂以治疗癌症的吲哚衍生物
TW202237119A (zh)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Ａｌｋ﹘５抑制劑和彼之用途
CN117396472A (zh)	2020-12-22	2024-01-12	上海齐鲁锐格医药研发有限公司	Sos1抑制剂及其用途
US12037346B2 (en)	2021-04-13	2024-07-16	Nuvalent, Inc.	Amino-substituted heteroaryls for treating cancers with EGFR mutations
KR20240004659A (ko)	2021-04-30	2024-01-11	셀진 코포레이션	감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
WO2022235870A1 (fr)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Inhibiteurs de ras pour le traitement du cancer
AR125782A1 (es)	2021-05-05	2023-08-16	Revolution Medicines Inc	Inhibidores de ras
CN117500811A (zh)	2021-05-05	2024-02-02	锐新医药公司	共价ras抑制剂及其用途
EP4347041A1 (fr)	2021-05-28	2024-04-10	Taiho Pharmaceutical Co., Ltd.	Petites molécules inhibitrices de protéines mutées par kras
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
JP2025500878A (ja)	2021-12-17	2025-01-15	ジェンザイム・コーポレーション	Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
EP4227307A1 (fr)	2022-02-11	2023-08-16	Genzyme Corporation	Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2
CN119136806A (zh)	2022-03-08	2024-12-13	锐新医药公司	用于治疗免疫难治性肺癌的方法
KR20250022133A (ko)	2022-06-10	2025-02-14	레볼루션 메디슨즈, 인크.	거대고리 ras 억제제
JP2025525445A (ja)	2022-06-30	2025-08-05	ストロバイオファーマインコーポレーテッド	抗ｒｏｒ１抗体及び抗体コンジュゲート、抗ｒｏｒ１抗体又は抗体コンジュゲートを含む組成物、並びに抗ｒｏｒ１抗体及び抗体コンジュゲートを作製及び使用する方法
PE20251879A1 (es)	2022-10-14	2025-07-22	Black Diamond Therapeutics Inc	Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina
TW202504611A (zh)	2023-03-30	2025-02-01	美商銳新醫藥公司	用於誘導ｒａｓｇｔｐ水解之組合物及其用途
WO2024211712A1 (fr)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Composés macrocycliques condensés en tant qu'inhibiteurs de ras
WO2024211663A1 (fr)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Composés macrocycliques condensés en tant qu'inhibiteurs de ras
WO2024216016A1 (fr)	2023-04-14	2024-10-17	Revolution Medicines, Inc.	Formes cristallines d'un inhibiteur de ras
WO2024216048A1 (fr)	2023-04-14	2024-10-17	Revolution Medicines, Inc.	Formes cristallines d'inhibiteurs de ras, compositions les contenant et leurs procédés d'utilisation
TW202508595A (zh)	2023-05-04	2025-03-01	美商銳新醫藥公司	用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (fr)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
WO2025043187A1 (fr)	2023-08-24	2025-02-27	Otsuka Pharmaceutical Co., Ltd.	Combinaisons de doses fixes de cédazuridine et d'azacitidine
US20250154171A1 (en)	2023-10-12	2025-05-15	Revolution Medicines, Inc.	Ras inhibitors
WO2025081117A2 (fr)	2023-10-13	2025-04-17	Sutro Biopharma, Inc.	Anticorps anti-facteur tissulaire et conjugués d'anticorps, compositions comprenant des anticorps anti-facteur tissulaire ou des conjugués d'anticorps, et méthodes de fabrication et d'utilisation d'anticorps anti-facteur tissulaire et de conjugués d'anticorps
US20250136615A1 (en)	2023-10-20	2025-05-01	Merck Sharp & Dohme Llc	Small molecule inhibitors of kras proteins
WO2025137507A1 (fr)	2023-12-22	2025-06-26	Regor Pharmaceuticals, Inc.	Inhibiteurs de sos1 et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) *	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
US5929097A (en) *	1996-10-16	1999-07-27	American Cyanamid Company	Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

1998
- 1998-07-21 EP EP98930987A patent/EP1003720B1/fr not_active Expired - Lifetime
- 1998-07-21 KR KR10-2000-7001303A patent/KR100372138B1/ko not_active Expired - Fee Related
- 1998-07-21 AT AT98930987T patent/ATE263147T1/de not_active IP Right Cessation
- 1998-07-21 ES ES98930987T patent/ES2216293T3/es not_active Expired - Lifetime
- 1998-07-21 BR BR9811868-4A patent/BR9811868A/pt not_active Application Discontinuation
- 1998-07-21 CA CA002299355A patent/CA2299355C/fr not_active Expired - Fee Related
- 1998-07-21 WO PCT/IB1998/001113 patent/WO1999007675A1/fr not_active Application Discontinuation
- 1998-07-21 NZ NZ502309A patent/NZ502309A/en unknown
- 1998-07-21 ID IDW20000232A patent/ID23668A/id unknown
- 1998-07-21 JP JP2000506179A patent/JP3448275B2/ja not_active Expired - Fee Related
- 1998-07-21 YU YU1900A patent/YU1900A/sh unknown
- 1998-07-21 DE DE69822839T patent/DE69822839T2/de not_active Expired - Fee Related
- 1998-07-21 SK SK136-2000A patent/SK1362000A3/sk unknown
- 1998-07-21 EA EA200000096A patent/EA002490B1/ru not_active IP Right Cessation
- 1998-07-21 HU HU0002960A patent/HUP0002960A3/hu unknown
- 1998-07-21 IL IL13430098A patent/IL134300A/en not_active IP Right Cessation
- 1998-07-21 TR TR2000/00368T patent/TR200000368T2/xx unknown
- 1998-07-21 PT PT98930987T patent/PT1003720E/pt unknown
- 1998-07-21 PL PL98338633A patent/PL338633A1/xx unknown
- 1998-07-21 CN CNB988078961A patent/CN1171866C/zh not_active Expired - Fee Related
- 1998-07-21 UA UA2000020651A patent/UA61963C2/uk unknown
- 1998-07-21 US US09/380,163 patent/US6214872B1/en not_active Expired - Fee Related
- 1998-07-21 DK DK98930987T patent/DK1003720T3/da active
- 1998-07-21 AU AU81253/98A patent/AU730248B2/en not_active Ceased
- 1998-08-04 PE PE1998000696A patent/PE110899A1/es not_active Application Discontinuation
- 1998-08-05 TW TW087112896A patent/TW426662B/zh not_active IP Right Cessation
- 1998-08-05 DZ DZ980191A patent/DZ2581A1/fr active
- 1998-08-05 PA PA19988456801A patent/PA8456801A1/es unknown
- 1998-08-06 CO CO98045260A patent/CO4960658A1/es unknown
- 1998-08-06 AP APAP/P/1998/001313A patent/AP1220A/en active
- 1998-08-06 MY MYPI98003591A patent/MY120235A/en unknown
- 1998-08-07 MA MA25207A patent/MA26530A1/fr unknown
- 1998-08-07 GT GT199800124A patent/GT199800124A/es unknown
- 1998-08-07 ZA ZA9807126A patent/ZA987126B/xx unknown
- 1998-08-07 AR ARP980103929A patent/AR015419A1/es unknown
- 1998-08-07 TN TNTNSN98150A patent/TNSN98150A1/fr unknown
- 1998-08-07 HR HR980438A patent/HRP980438B1/xx not_active IP Right Cessation
- 1998-08-10 UY UY25131A patent/UY25131A1/es not_active IP Right Cessation
2000
- 2000-01-14 IS IS5340A patent/IS5340A/is unknown
- 2000-02-01 BG BG104118A patent/BG104118A/bg unknown
- 2000-02-04 OA OA1200000028A patent/OA11284A/en unknown
- 2000-02-07 NO NO20000604A patent/NO313189B1/no not_active IP Right Cessation
- 2000-04-04 UY UY26098A patent/UY26098A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
TNSN98150A1 (fr)	2005-03-15
YU1900A (sh)	2002-08-12
PA8456801A1 (es)	2000-05-24
UA61963C2 (en)	2003-12-15
HK1029575A1 (en)	2001-04-06
NO313189B1 (no)	2002-08-26
UY25131A1 (es)	2000-12-29
AU8125398A (en)	1999-03-01
ZA987126B (en)	2000-02-07
NZ502309A (en)	2002-02-01
KR100372138B1 (ko)	2003-02-14
PE110899A1 (es)	1999-11-12
DK1003720T3 (da)	2004-05-10
HRP980438B1 (en)	2003-04-30
CA2299355A1 (fr)	1999-02-18
PT1003720E (pt)	2004-07-30
NO20000604L (no)	2000-02-07
ID23668A (id)	2000-05-11
IS5340A (is)	2000-01-14
ATE263147T1 (de)	2004-04-15
OA11284A (en)	2003-07-30
EP1003720B1 (fr)	2004-03-31
EP1003720A1 (fr)	2000-05-31
CN1171866C (zh)	2004-10-20
HUP0002960A3 (en)	2001-12-28
AU730248B2 (en)	2001-03-01
HRP980438A2 (en)	1999-12-31
TR200000368T2 (tr)	2000-07-21
IL134300A (en)	2004-07-25
UY26098A1 (es)	2001-12-28
JP2001512713A (ja)	2001-08-28
CA2299355C (fr)	2005-09-27
HUP0002960A2 (hu)	2001-07-30
ES2216293T3 (es)	2004-10-16
AR015419A1 (es)	2001-05-02
GT199800124A (es)	2000-01-29
DZ2581A1 (fr)	2003-02-22
BG104118A (bg)	2000-09-29
AP9801313A0 (en)	1998-09-30
MA26530A1 (fr)	2004-12-20
CN1265646A (zh)	2000-09-06
JP3448275B2 (ja)	2003-09-22
EA200000096A1 (ru)	2000-10-30
TW426662B (en)	2001-03-21
NO20000604D0 (no)	2000-02-07
IL134300A0 (en)	2001-04-30
BR9811868A (pt)	2000-08-15
AP1220A (en)	2003-10-24
US6214872B1 (en)	2001-04-10
DE69822839T2 (de)	2004-08-19
DE69822839D1 (de)	2004-05-06
KR20010022707A (ko)	2001-03-26
MY120235A (en)	2005-09-30
PL338633A1 (en)	2000-11-06
WO1999007675A1 (fr)	1999-02-18
EA002490B1 (ru)	2002-06-27
CO4960658A1 (es)	2000-09-25

Publication	Publication Date	Title
SK1362000A3 (en)	2000-10-09	Aryloxyarylsulfonylamino hydroxamic acid derivatives
AP733A (en)	1999-02-12	Arylsulfonylamino hydroxamic acid derivatives.
AP826A (en)	2000-04-28	Arysulfonylamino hydroxamic acid derivatives.
CA2268484C (fr)	2006-02-07	Derives d'acide hydroxamique aryloxyarylsulfonylamino de cyclobutyle
WO1998034915A1 (fr)	1998-08-13	Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
EP0895988B1 (fr)	2002-05-22	Dérivés de l'acide arylsulfonamino-hydroxamique
US6300337B1 (en)	2001-10-09	Acetamide derivative and use thereof
DE69907337T2 (de)	2004-02-26	Hydroxamsäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
CZ2000306A3 (cs)	2000-07-12	Deriváty aryloxyarylsulfonylaminohydroxamové kyseliny
EP1415984A1 (fr)	2004-05-06	Dérivés de l'acide aryloxyarylsulfonylaminohydroxamique
US6107337A (en)	2000-08-22	Arylsulfonylamino hydroxamic acid derivatives
MXPA00001349A (en)	2001-05-07	Aryloxyarylsulfonylamino hydroxamic acid derivatives
IL314855A (en)	2024-10-01	Preparation method of nitrogen-containing heterocyclic compound
HK1029575B (en)	2005-04-01	Aryloxyarylsulfonylamino hydroxamic acid derivatives
MXPA99010152A (en)	2000-05-01	Hydroxyamide derivatives of 5-oxo-pirrolidine-2-carboxyl acid